Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center

Journal of Rheumatology

Volumn 40, Issue 12, 2013, Pages 2047-2051

  Tombetti, Enrico ^a   Franchini, Stefano ^a   Papa, Maurizio ^a   Sabbadini, Maria Grazia ^a   Baldissera, Elena ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Interleukin 6; Takayasu arteritis; Tocilizumab; Vasculitis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALPHA GLOBULIN; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETA GLOBULIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ADULT; AORTA ARCH SYNDROME; ARTICLE; BASOPHIL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME BLOOD LEVEL; EOSINOPHIL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MACULOPAPULAR RASH; MONOCYTE; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VASCULAR LESION;

INTERLEUKIN 6; TAKAYASU ARTERITIS; TOCILIZUMAB; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; ITALY; MAGNETIC RESONANCE IMAGING; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TAKAYASU ARTERITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888994181     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130536     Document Type: Article

References (20)

1. Mason JC. Takayasu arteritis - advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406-15.
2. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007;33:777-86, vi.
3. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 2011;11:61-7.
4. Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011;23:273-7.
5. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006;45:545-8.
6. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55-60.
7. Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996;93:1788-90.
8. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-9.
9. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
10. Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32:703-9.
11. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58:1197-200.
12. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156.
13. Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;1 Suppl 70:S90-3.
14. Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;1 Suppl 70:S98-100.
15. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720-9.
16. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51:151-6.
17. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567-9.
18. Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995;21:1041-58.
19. Xenitidis T, Horger M, Zeh G, Kanz L, Henes JC. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology 2013;52:1729-31.
20. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155:425-33.